Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 9/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 3/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802055 | 0.83 | — | — | |
| SCHEMBL955326 | 0.78 | NPC1 (0.42) | — | |
| SCHEMBL2801403 | 0.77 | HSD17B10 (0.38) | TSHRL3MBTL1 | |
| SCHEMBL10240090 | 0.73 | KDM4C (0.38) | HCAR2 | |
| SCHEMBL2802788 | 0.73 | L3MBTL1 (0.40) | CETPTSHRL3MBTL1 | |
| SCHEMBL15871949 | 0.73 | KDM4E (0.42) | L3MBTL1 | |
| SCHEMBL15652942 | 0.73 | CETP (0.38) | CETPTSHR | |
| SCHEMBL3937442 | 0.72 | CFTR (0.35) | — | |
| SCHEMBL2803594 | 0.71 | TP53 (0.38) | L3MBTL1 | |
| SCHEMBL2803444 | 0.71 | CDK2 (0.37) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845973-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-9051278-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2015-06-09 | — | — | US | disclosed |
| EP-2256106-B1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | ASTEX THERAPEUTICS LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-20140371213-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | ASTEX THERAPEUTICS, LTD. (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8779147-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8404718-B2 | Combinations of pyrazole kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| EP-1651612-B9 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2012-09-05 | — | — | EP | disclosed |
| US-20120213791-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | ASTEX THERAPEUTICS, LTD. (GB) | 2012-08-23 | — | — | US | disclosed |
| CN-1826323-B | 3, 4-disubstituted 1H-pyrazole compounds and their use as modulators of Cyclin Dependent Kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) | ASTEX THERAPEUTICS LTD | 2012-06-27 | — | — | CN | disclosed |
| CN-101146532-B | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD | 2012-05-09 | — | — | CN | disclosed |
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ASTEX THERAPEUTICS LIMITED (UK) | 2008-07-03 | — | — | US | disclosed |
| US-7385059-B2 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| CN-101146533-A | Combinations of pyrazole kinase inhibitors and further antitumor agents | ASTEX THERAPEUTICS LTD (GB) | 2008-03-19 | — | — | CN | disclosed |
| CN-101146532-A | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2008-03-19 | — | — | CN | disclosed |
| CN-101146531-A | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2008-03-19 | — | — | CN | disclosed |
| WO-2008009954-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| EP-1845973-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| US-20060194843-A1 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide | ASTEX THERAPEUTICS LIMITED (GB) | 2006-08-31 | — | — | US | disclosed |
| CN-1826323-A | 3, 4-disubstituted 1H-pyrazole compounds and their use as modulators of Cyclin Dependent Kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) | ASTEX THERAPEUTICS LTD (GB) | 2006-08-30 | — | — | CN | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194843-A1 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide | CDK1, CDK3, ROS1 | CETP 4819/4885BTK 1110/4885PARP1 1031/4885 |
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ROS1, CDK9, GRK4 | CETP 4844/4885BTK 286/4885PARP1 1815/4885 |
| US-20120213791-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | CDK3, CDK1, CDKL3 | CETP 4573/4885BTK 646/4885PARP1 821/4885 |
| US-20140371213-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | CDK1, CDK3, CDK13 | CETP 4786/4885BTK 434/4885PARP1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.